JP2015508846A - アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法 - Google Patents

アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法 Download PDF

Info

Publication number
JP2015508846A
JP2015508846A JP2014560000A JP2014560000A JP2015508846A JP 2015508846 A JP2015508846 A JP 2015508846A JP 2014560000 A JP2014560000 A JP 2014560000A JP 2014560000 A JP2014560000 A JP 2014560000A JP 2015508846 A JP2015508846 A JP 2015508846A
Authority
JP
Japan
Prior art keywords
alkylated cyclodextrin
less
cyclodextrin composition
alkylated
cyclodextrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014560000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015508846A5 (cg-RX-API-DMAC7.html
Inventor
ビンセント ディー. アントル
ビンセント ディー. アントル
Original Assignee
サイデックス・ファーマシューティカルズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49083249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2015508846(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by サイデックス・ファーマシューティカルズ・インコーポレイテッド filed Critical サイデックス・ファーマシューティカルズ・インコーポレイテッド
Publication of JP2015508846A publication Critical patent/JP2015508846A/ja
Publication of JP2015508846A5 publication Critical patent/JP2015508846A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B32/00—Carbon; Compounds thereof
    • C01B32/30—Active carbon
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B32/00—Carbon; Compounds thereof
    • C01B32/30—Active carbon
    • C01B32/354—After-treatment
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B32/00—Carbon; Compounds thereof
    • C01B32/30—Active carbon
    • C01B32/354—After-treatment
    • C01B32/378—Purification
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014560000A 2012-02-28 2013-02-27 アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法 Pending JP2015508846A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261604504P 2012-02-28 2012-02-28
US61/604,504 2012-02-28
PCT/US2013/028094 WO2013130666A1 (en) 2012-02-28 2013-02-27 Alkylated cyclodextrin compositions and processes for preparing and using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016085851A Division JP6517725B2 (ja) 2012-02-28 2016-04-22 アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法

Publications (2)

Publication Number Publication Date
JP2015508846A true JP2015508846A (ja) 2015-03-23
JP2015508846A5 JP2015508846A5 (cg-RX-API-DMAC7.html) 2015-11-12

Family

ID=49083249

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014560000A Pending JP2015508846A (ja) 2012-02-28 2013-02-27 アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法
JP2016085851A Active JP6517725B2 (ja) 2012-02-28 2016-04-22 アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法
JP2018000617A Pending JP2018048350A (ja) 2012-02-28 2018-01-05 アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016085851A Active JP6517725B2 (ja) 2012-02-28 2016-04-22 アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法
JP2018000617A Pending JP2018048350A (ja) 2012-02-28 2018-01-05 アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法

Country Status (11)

Country Link
US (2) US9493582B2 (cg-RX-API-DMAC7.html)
EP (1) EP2748205A4 (cg-RX-API-DMAC7.html)
JP (3) JP2015508846A (cg-RX-API-DMAC7.html)
KR (3) KR20160033795A (cg-RX-API-DMAC7.html)
CN (2) CN110066351B (cg-RX-API-DMAC7.html)
AU (2) AU2013226073B2 (cg-RX-API-DMAC7.html)
CA (1) CA2865950C (cg-RX-API-DMAC7.html)
HK (1) HK1211311A1 (cg-RX-API-DMAC7.html)
MX (2) MX353603B (cg-RX-API-DMAC7.html)
RU (2) RU2747757C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013130666A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023502399A (ja) * 2019-11-18 2023-01-24 サイデックス・ファーマシューティカルズ・インコーポレイテッド アルキル化シクロデキストリン組成物並びにこれを製造及び使用する方法
JP2023529033A (ja) * 2020-04-09 2023-07-07 ビカ・バイオテック(グアンジョウ)・カンパニー・リミテッド ベンダムスチン組成物及びその用途
JP2023549292A (ja) * 2020-10-27 2023-11-22 バイヨン・セラピューティクス・インコーポレイテッド アゾベンゼン光反応性化合物の製剤

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
JP5675629B2 (ja) 2008-10-21 2015-02-25 オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. ペプチドエポキシケトンを用いた併用療法
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
HUE058834T2 (hu) 2012-02-15 2022-09-28 Cydex Pharmaceuticals Inc Elõállítási eljárás ciklodextrin-származékokhoz
MX353603B (es) 2012-02-28 2018-01-19 Cydex Pharmaceuticals Inc Composiciones de ciclodextrina alquilada y procesos para preparar y utilizar las mismas.
AU2013259573B2 (en) 2012-05-08 2018-02-15 Onyx Therapeutics, Inc. Cyclodextrin complexation Methods for Formulating Peptide Proteasome Inhibitors
WO2014066274A1 (en) * 2012-10-22 2014-05-01 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
MX363386B (es) 2013-10-03 2019-03-20 Dow Pharmaceutical Sciences Formulaciones de efinaconazol estabilizadas.
KR102612453B1 (ko) 2013-11-22 2023-12-08 다우 파마슈티컬 사이언시즈, 인코포레이티드 항­감염 방법,조성물,및 장치
CN103694376B (zh) 2014-01-10 2016-04-13 凯莱英医药集团(天津)股份有限公司 一种制备磺丁基醚-β-环糊精的方法
HUE063851T2 (hu) 2014-08-22 2024-02-28 Cydex Pharmaceuticals Inc Frakcionált alkilezett ciklodextrin készítmények és eljárás ezek elõállítására és alkalmazására
JP6706799B2 (ja) 2014-12-19 2020-06-10 国立大学法人 長崎大学 新規ビスホスホン酸誘導体及びその用途
CN105016334A (zh) * 2015-08-22 2015-11-04 钱景 一种烷基化环糊精还原氧化石墨烯的方法
FR3042501B1 (fr) * 2015-10-16 2017-11-03 Roquette Freres Nouvelles cyclodextrines methylees et leurs procedes de preparation
CA3014294A1 (en) 2016-02-18 2017-08-24 Melinta Therapeutics, Inc. Oritavancin formulations
CN116869983A (zh) * 2016-09-16 2023-10-13 锡德克斯药物公司 包含对乙酰氨基酚和磺烷基醚环糊精的制剂
BR112020005079A2 (pt) 2017-09-14 2020-09-15 Glaxosmithkline Intellectual Property Development Limited tratamento de combinação para câncer
BR112020004729A2 (pt) * 2017-09-20 2020-09-15 Kao Corporation composição em pó compreendendo corantes diretos para o cabelo
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
EP3766475A1 (en) 2019-07-15 2021-01-20 OP-Hygiene IP GmbH Wipes
DE102019133243A1 (de) * 2019-12-05 2021-06-10 Rheinische Friedrich-Wilhelms-Universität Bonn Verfahren zur Herstellung sprühgefriergetrockneter Partikel und entsprechend hergestellte Partikel
US12698348B2 (en) 2020-09-24 2026-08-04 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
CN113275306B (zh) * 2021-04-19 2022-09-23 龙岩市华研活性炭科技有限公司 动态旋流活性炭酸洗机
US11649299B2 (en) 2021-06-10 2023-05-16 Cyclolab Cyclodextrin Research And Development Laboratory Ltd. Purification of sulfobutylated cyclodextrins with specific ion exchange resins
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
US20250295771A1 (en) 2022-05-11 2025-09-25 Celgene Corporation Methods and uses related to t cell therapy and production of same
CN115166115B (zh) * 2022-07-20 2024-07-09 宁波工程学院 鱼肉中多种汞形态含量检测的样品前处理方法及检测方法
CN115505052B (zh) * 2022-08-23 2023-05-23 安徽普利药业有限公司 一种β-环糊精衍生物的制备方法
US20260166082A1 (en) 2022-11-02 2026-06-18 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
EP4685151A1 (en) 2024-07-24 2026-01-28 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Proteasome inhibitor
CN120505152A (zh) * 2025-05-12 2025-08-19 东莞市建文洗涤用品有限公司 一种除菌除味的强力洁厕液及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1160610A (ja) * 1997-07-01 1999-03-02 Pfizer Prod Inc シクロデキストリンを製造するための方法
WO2009018069A2 (en) * 2007-07-30 2009-02-05 Cydex Pharmaceuticals, Inc Mixtures of cyclodextrin derivatives
JP2010539193A (ja) * 2008-04-28 2010-12-16 サイデックス・ファーマシューティカルズ・インコーポレイテッド スルホアルキルエーテルシクロデキストリン組成物

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US472706A (en) 1892-04-12 Elias m
US2744938A (en) 1952-07-24 1956-05-08 Universal Oil Prod Co Removal of color impurities from organic compounds
US3033900A (en) 1958-03-25 1962-05-08 Pfanstiehl Lab Inc Method of preparing calcium glucoheptonate
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3453257A (en) 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3453259A (en) 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
JPS5953038B2 (ja) 1979-04-07 1984-12-22 メルシャン株式会社 サイクロデキストリンの製造法
NL8104410A (nl) 1981-09-24 1983-04-18 Proefstation Voor Aardappelver Werkwijze ter bereiding van cyclodextrine.
JPS5862152A (ja) 1981-10-08 1983-04-13 Microbial Chem Res Found N−〔4−(3−アミノプロピル)アミノブチル〕−2−(ω−グアニジノ脂肪酸アミド)−2−ヒドロキシエタンアミドおよびその誘導体ならびにその製造法
EP0147685B1 (de) 1983-12-17 1989-04-26 Hoechst Aktiengesellschaft Ether des beta-Cyclodextrins und ein Verfahren zu ihrer Herstellung
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
JPS61169149A (ja) 1985-01-22 1986-07-30 Nippon Mining Co Ltd 連続鋳造方法
US4597946A (en) 1985-04-30 1986-07-01 Uop Inc. Vertical tube reactor with serial downward flow through a plurality of sets of particulate containing tubes
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US4920214A (en) 1986-04-16 1990-04-24 American Maize-Products Company Process for producing modified cyclodextrins
US4738923A (en) 1986-05-20 1988-04-19 American Maize-Products Company Process for producing and separating cyclodextrins
ES2062988T3 (es) 1986-12-19 1995-01-01 Sankyo Co Nuevos oligopeptidos inhibidores de la renina, su preparacion y su uso.
US5183809A (en) 1990-02-15 1993-02-02 The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation Cyclodextrin polymers and cyclodextrins immobilized on a solid surface
US5019562A (en) 1988-01-19 1991-05-28 The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation Growth inhibiting agent and the use thereof
US5135919A (en) 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
US5760015A (en) 1988-01-19 1998-06-02 The Trustees Of The University Of Pennsylvania Cyclodextrin compounds and methods of making and use thereof
US5658894A (en) 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
US4904306A (en) 1988-07-22 1990-02-27 American Maize-Products Company Separation and purification of gamma cyclodextrin
US5173481A (en) 1989-04-03 1992-12-22 The United States Of America As Represented By The Department Of Health And Human Services Preparation of specifically substituted cyclodextrins
WO1990012035A1 (en) 1989-04-03 1990-10-18 Janssen Pharmaceutica N.V. Regioselective substitutions in cyclodextrins
US5257985A (en) 1989-12-04 1993-11-02 Richard Puhl Multi-chamber intravenous bag apparatus
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
KR927003645A (ko) 1990-05-21 1992-12-18 후지다 히로미찌 씨클로덱스트린 유도체
JP2905573B2 (ja) 1990-06-28 1999-06-14 日本食品化工株式会社 ヒドロキシアルキル化シクロデキストリン精製物及びその製造法
FR2668163B1 (fr) 1990-10-18 1993-01-15 Orsan Procede de fabrication de beta-cyclodextrine.
JPH051102A (ja) 1991-05-29 1993-01-08 Toppan Printing Co Ltd シクロデキストリン誘導体
CN1072185A (zh) 1991-11-13 1993-05-19 美国玉米产品公司 制备非混浊型环糊精的方法
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
DE69322721T2 (de) 1992-09-24 1999-06-10 Terumo K.K., Tokio/Tokyo Sulfonierte Verbindungen aus Beta-Cyclodextrinpolymer und diese enthaltendes Medikament welches die Hyperplasie von Gefässwanden hemmt
FR2705963B1 (fr) 1993-06-03 1995-07-13 Commissariat Energie Atomique Dérivés sulfonés de cyclomalto-oligosaccharides, leur procédé de préparation et support de substances actives contenant ces dérivés.
US5393880A (en) 1993-06-17 1995-02-28 American Maize-Products Company Cyclodextrin refining process
DE4333598A1 (de) 1993-10-01 1995-04-06 Consortium Elektrochem Ind Verfahren zur Herstellung von alkylierten Cyclodextrin-Derivaten, nach dem Verfahren herstellbare methylierte Cyclodextrin-Derivate und die Verwendung der Produkte
US5479254A (en) 1993-10-22 1995-12-26 Woskov; Paul P. Continuous, real time microwave plasma element sensor
US5661151A (en) 1993-12-21 1997-08-26 Schering Corporation Tetrahydrofuran antifungals
DE4401618A1 (de) 1994-01-20 1995-07-27 Consortium Elektrochem Ind Verfahren zur Herstellung von aminofunktionellen Cyclodextrin Derivaten
US5658390A (en) 1994-06-29 1997-08-19 American Maize-Products Company Purification of beta cyclodextrin
DE4428654A1 (de) 1994-08-12 1996-02-15 Consortium Elektrochem Ind Wasserlösliche Cyclodextrinderivate mit lipophilen Substituenten und Verfahren zu ihrer Herstellung
US5550222A (en) 1994-12-14 1996-08-27 American Maize-Products Company Process for producing gamma-cyclodextrin
DE4446891A1 (de) 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
DE19505263A1 (de) * 1995-02-16 1996-08-22 Consortium Elektrochem Ind Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten
US5569756A (en) 1995-03-21 1996-10-29 American Maize-Products Company Purification of chemically modified cyclodextrins
FR2735136B1 (fr) 1995-06-08 1997-08-14 Roquette Freres Composition pulverulente d'hydroxypropyl-betacyclodextrine et son procede de preparation.
US5935941A (en) 1997-10-24 1999-08-10 Pitha; Josef Alkylations of cyclodextrins leading to derivatives which have a ridgidly extended cavity
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6033573A (en) 1997-05-29 2000-03-07 The United States Of America As Represented By The Secretary Of Agriculture Activated nutshell carbons from agricultural waste
ES2210769T3 (es) 1997-06-13 2004-07-01 Cydex Inc. Compuesto con vida de almacenamiento prolongada que comprende ciclodextrina y medicamentos y promedicamentos que se descomponen en componentes insolubles en agua.
US6316613B1 (en) 1997-07-25 2001-11-13 Beckman Coulter, Inc. Chiral separation of pharmaceutical compounds with charged cyclodextrins using capillary electrophoresis
US6165484A (en) 1997-08-26 2000-12-26 Wake Forest University EDTA and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections
EP1017427B1 (en) 1997-08-26 2006-04-26 Board of Regents, The University of Texas System Use of a composition comprising a chelating agent and an antimicrobial compound for the treatment of biofilms
US6391862B1 (en) 1997-10-14 2002-05-21 The Texas A&M University System Chiral resolving agents for enantioseparations
WO1999027932A1 (en) 1997-12-01 1999-06-10 Schering Corporation Injectable antifungal formulations
WO1999042111A1 (en) 1998-02-23 1999-08-26 Cyclops, Ehf. High-energy cyclodextrin complexes
TW394749B (en) 1998-03-05 2000-06-21 Deng Jian Lang Method of manufacturing active carbon by using carbon black
AT410321B (de) 1998-08-11 2003-03-25 Tulln Zuckerforschung Gmbh Verfahren zur herstellung von cyclodextrin
US6831099B1 (en) 1999-05-12 2004-12-14 Yale University Enzyme inhibition
DE19930553A1 (de) 1999-07-02 2001-01-11 Wacker Chemie Gmbh Verfahren zur Herstellung von alkylierten Cyclodextrin-Derivaten
TWI242015B (en) 1999-11-29 2005-10-21 Akzo Nobel Nv 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
US6479467B1 (en) 1999-12-16 2002-11-12 Eastman Chemical Company Cyclodextrin ethers
FR2808691B1 (fr) 2000-05-12 2005-06-24 Coletica Cyclodextrines substituees preferentiellement sur leur face primaire par des fonctions acide ou amine
WO2002055562A2 (en) 2001-01-11 2002-07-18 Eastman Chem Co Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials
EP1383445A4 (en) 2001-03-20 2005-04-13 Cydex Inc FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US6869939B2 (en) 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
MXPA05002728A (es) 2002-09-13 2005-07-25 Cydex Inc Capsulas que contienen composiciones de relleno acuoso estabilizadas con ciclodextrina derivada.
WO2005042584A2 (en) 2003-10-31 2005-05-12 The University Of Kansas Sulfoalkyl ether-alkyl ether cyclodextrin derivatives
US20070020298A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020196A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
BRPI0510119A (pt) 2004-04-23 2007-09-25 Cydex Inc formulação para dpi contendo sulfoaquil éter de ciclodextrina
BRPI0509592A (pt) 2004-05-06 2007-09-25 Cydex Inc formulações de sabor mascarado, contendo sertralina e ciclodextrina de éter de sulfoalquila
US7559241B2 (en) 2004-05-27 2009-07-14 Sulphco, Inc. High-throughput continuous-flow ultrasound reactor
US20060009469A1 (en) 2004-05-28 2006-01-12 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmacutical compositions of posaconazole
MXPA06014013A (es) 2004-06-08 2007-03-15 Metabasis Therapeutics Inc Sintesis mediada por acidos de lewis de esteres ciclicos.
EP2261236B1 (en) 2004-12-07 2015-07-15 Onyx Therapeutics, Inc. Composition for proteasome inhibition
US20060128653A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
WO2007047253A2 (en) 2005-10-11 2007-04-26 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
SI2952197T1 (sl) 2005-10-26 2017-09-29 Cydex Pharmaceuticals, Inc. Sestavki sulfoalkil eter ciklodekstrina in metode priprave le-tega
CN100503647C (zh) 2005-11-02 2009-06-24 南京师范大学 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
US20090239942A1 (en) 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
PL2061458T3 (pl) 2006-09-15 2015-07-31 Univ Minnesota Kompozycje topiramatu i sposoby ich stosowania
CN101686681B (zh) 2007-04-27 2015-04-01 锡德克斯药物公司 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法
EP1992334A1 (en) 2007-05-08 2008-11-19 Docpharma NV/SA Storage-stable formulation of oxidation-sensitive phenolic drug, especially paracetamol, comprises aqueous drug solution deoxygenated by a temperature-controlled manufacturing process of the formulation
US7834612B2 (en) * 2007-07-26 2010-11-16 Altronix Corporation Method and apparatus for regulating voltage in a remote device
EP2018866A1 (en) 2007-07-27 2009-01-28 Sandoz AG Pharmaceutical compositions containing voriconazole
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
CA2701778C (en) 2007-10-04 2018-09-11 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
EP2278957A2 (en) 2008-04-15 2011-02-02 Schering Corporation Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
PL3100728T3 (pl) 2009-05-13 2020-05-18 Cydex Pharmaceuticals, Inc. Kompozycje farmaceutyczne zawierające prasugrel i pochodne cyklodekstryny oraz sposoby ich wytwarzania i zastosowania
KR101522918B1 (ko) 2009-05-29 2015-05-27 사이덱스 파마슈티칼스, 인크. 사이클로덱스트린 유도체를 포함하는 주사용 멜팔란 조성물 및 이의 제조 및 사용 방법
US8492538B1 (en) 2009-06-04 2013-07-23 Jose R. Matos Cyclodextrin derivative salts
CN102040675B (zh) 2010-12-22 2012-10-03 石药集团中诺药业(石家庄)有限公司 一种羟丙基-β-环糊精的制备方法
HUE058834T2 (hu) * 2012-02-15 2022-09-28 Cydex Pharmaceuticals Inc Elõállítási eljárás ciklodextrin-származékokhoz
MX353603B (es) 2012-02-28 2018-01-19 Cydex Pharmaceuticals Inc Composiciones de ciclodextrina alquilada y procesos para preparar y utilizar las mismas.
WO2014066274A1 (en) 2012-10-22 2014-05-01 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
HUE063851T2 (hu) 2014-08-22 2024-02-28 Cydex Pharmaceuticals Inc Frakcionált alkilezett ciklodextrin készítmények és eljárás ezek elõállítására és alkalmazására
CN104892797B (zh) 2015-05-28 2017-03-22 天津大学 特定平均取代度磺丁基醚‑β‑环糊精的合成方法
CN104974275A (zh) 2015-07-30 2015-10-14 淄博千汇生物科技有限公司 磺烷基醚环糊精衍生物的合成方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1160610A (ja) * 1997-07-01 1999-03-02 Pfizer Prod Inc シクロデキストリンを製造するための方法
WO2009018069A2 (en) * 2007-07-30 2009-02-05 Cydex Pharmaceuticals, Inc Mixtures of cyclodextrin derivatives
JP2010539193A (ja) * 2008-04-28 2010-12-16 サイデックス・ファーマシューティカルズ・インコーポレイテッド スルホアルキルエーテルシクロデキストリン組成物

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023502399A (ja) * 2019-11-18 2023-01-24 サイデックス・ファーマシューティカルズ・インコーポレイテッド アルキル化シクロデキストリン組成物並びにこれを製造及び使用する方法
JP7686639B2 (ja) 2019-11-18 2025-06-02 サイデックス・ファーマシューティカルズ・インコーポレイテッド アルキル化シクロデキストリン組成物並びにこれを製造及び使用する方法
JP2023529033A (ja) * 2020-04-09 2023-07-07 ビカ・バイオテック(グアンジョウ)・カンパニー・リミテッド ベンダムスチン組成物及びその用途
JP2023549292A (ja) * 2020-10-27 2023-11-22 バイヨン・セラピューティクス・インコーポレイテッド アゾベンゼン光反応性化合物の製剤

Also Published As

Publication number Publication date
RU2016140391A3 (cg-RX-API-DMAC7.html) 2020-02-21
AU2016210707A1 (en) 2016-08-25
MX353603B (es) 2018-01-19
CN110066351B (zh) 2022-06-14
MX2014010323A (es) 2014-12-08
WO2013130666A1 (en) 2013-09-06
CN104704007A (zh) 2015-06-10
US20170158781A1 (en) 2017-06-08
EP2748205A4 (en) 2014-07-30
HK1211311A1 (en) 2016-05-20
EP2748205A1 (en) 2014-07-02
MX390762B (es) 2025-03-19
KR20150004797A (ko) 2015-01-13
AU2016210707B2 (en) 2018-03-08
CA2865950A1 (en) 2013-09-06
KR20200106100A (ko) 2020-09-10
RU2016140391A (ru) 2018-12-14
KR101633479B1 (ko) 2016-07-08
US20150045311A1 (en) 2015-02-12
RU2747757C2 (ru) 2021-05-13
JP6517725B2 (ja) 2019-05-22
RU2014136206A (ru) 2016-04-20
US10323103B2 (en) 2019-06-18
KR20160033795A (ko) 2016-03-28
AU2013226073A1 (en) 2014-10-02
CA2865950C (en) 2016-12-20
RU2615385C2 (ru) 2017-04-04
US9493582B2 (en) 2016-11-15
CN110066351A (zh) 2019-07-30
JP2016166368A (ja) 2016-09-15
JP2018048350A (ja) 2018-03-29
AU2013226073B2 (en) 2016-05-05

Similar Documents

Publication Publication Date Title
JP6444548B2 (ja) スルホアルキルエーテルシクロデキストリン組成物
JP6517725B2 (ja) アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法
JP6557144B2 (ja) アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法
AU2020386378B2 (en) Alkylated cyclodextrin compositions and processes for preparing and using the same
HK40075574A (en) Alkylated cyclodextrin compositions and processes for preparing and using the same
HK1214284B (en) Alkylated cyclodextrin compositions and processes for preparing and using the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141119

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140903

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150203

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20150203

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20150313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150318

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150526

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150611

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150714

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150917

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20150917

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151224